Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan for ctDNA-positive HER2-positive resected gastroesophageal adenocarcinoma
ISRCTN15960722Phase 2Active, not recruiting
- Sponsor
- University of Southampton
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in gastroesophageal junction adenocarcinoma, sponsored by University of Southampton. Primary endpoint: ctDNA clearance after 4 cycles. Started Apr 2024; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ISRCTN15960722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15960722.